# Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

> **NCT03176459** · PHASE4 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 186 (actual)

## Conditions studied

- C-Section
- Pain Management

## Interventions

- **DRUG:** Exparel + Bupivacaine
- **DRUG:** Bupivacaine

## Key facts

- **NCT ID:** NCT03176459
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2018-11-20
- **Final completion:** 2018-12-04
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03176459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03176459, "Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03176459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*